GlyTherix Ltd.
GlyTherix Ltd is an Australian targeted radiotherapy company specializing in therapeutics for solid tumors, including prostate, bladder and pancreas. GlyTherix is developing Miltuximab® for the targeted treatment of a number of cancers. At the core of the technology is a protein known as Glypican-1 (GPC-1). GPC-1 occurs in many solid tumors such as prostate, bladder, pancreatic, glioblastoma, esophageal, ovarian and brain cancers. It is not present in healthy tissue.
Tech Stack (20 technologies)
Frequently Asked Questions
What technologies does GlyTherix Ltd. use?+
GlyTherix Ltd. uses 20 technologies including Contact Form 7, Divi, Google Analytics.
What industry is GlyTherix Ltd. in?+
GlyTherix Ltd. operates in the Oncology industry.
Where is GlyTherix Ltd. based?+
GlyTherix Ltd. is headquartered in Australia.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026